Clinical significance of human papilloma virus infection in the cervical lesions

Abstract

Cervical lesions have been regarded as the common and frequently occurring diseases in China. Recently, the morbidity and youth tendency of cervical cancer have gradually increased. Cervical cancer, related with human papilloma virus (HPV) infection, has been one of the severest diseases threatening health and life of women, and is an infectious disease. The universality of HPV infection in the reproductive tract should not be ignored. The well-known risk factors of HPV infection in cervical lesions consist of high-risk sexual behaviors, immunosuppression, age, contraceptive methods, the concurrent infection of other sexually transmitted diseases, etc. The variation of cervical lesions induced by HPV infection is involved in the continuous pathological process, including the subclinical, latent, and persistent infection of high risk (HR)-HPV, chronic cervicitis with abnormal results of cytological examination, cervical intraepithelial neoplasia (CIN), and cervical cancer. The outcome of patients with HPV infection is influenced by many factors, such as HPV subtype dominance, persistent HPV infection, HPV loading dose, and multiple HPV infection. Controlling HR-HPV persistent infection should be an important strategy for reducing cervical lesions.

Keywords

cervical lesion / high risk-human papilloma virus / persistent infection / loading dose / cervical intraepithelial neoplasia / cervical cancer

References

[1] BekkersR L, MassugerL F, BultenJ, MelchersW J. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol, 2004, 14(2): 95–105

[2] HerreroR, HildesheimA, BrattiC, ShermanM E, HutchinsonM, MoralesJ, BalmacedaI, GreenbergM D, AlfaroM, BurkR D, WacholderS, PlummerM, SchiffmanM. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst, 2000, 92(6): 464–474

[3] InfantolinoC, FabrisP, InfantolinoD, BiasinM R, VenzaE, TosittiG, MinucciD. Usefulness of human papilloma virus testing in the screening of cervical cancer precursor lesions: a retrospective study in 314 cases. Eur J Obstet Gynecol Reprod Biol, 2000, 93(1): 71–75

[4] SellorsJ W, MahonyJ B, KaczorowskiJ, LytwynA, BanguraH, ChongS, LorinczA, DalbyD M, JanjusevicV, KellerJ L. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ, 2000, 163(5): 503–508

[5] DuttaguptaC, SenguptaS, RoyM, SenguptaD, ChakrabortyS, BhattacharyaP, RoyS, GhoshS. Oncogenic human papillomavirus (HPV) infection and uterine cervical cancer: a screening strategy in the perspective of rural India. Eur J Cancer Prev, 2002, 11(5): 447–456

[6] BoschF X, LorinczA, MunozN, MeijerC J, ShahK V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002, 55(4): 244–265

[7] DeaconJ M, EvansC D, YuleR, DesaiM, BinnsW, TaylorC, PetoJ. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer, 2000, 83(11): 1565–1572

[8] de Lima SoaresV, de MesquitaA M, CavalcanteF G, SilvaZ P, HoraV, DiedrichT, de Carvalho SilvaP, de MeloP G, DacalA R, de CarvalhoE M, FeldmeierH. Sexually transmitted infections in a female population in rural north-east Brazil: prevalence, morbidity and risk factors. Trop Med Int Health, 2003, 8(7): 595–603

[9] HeardI P, TassieJ M P, SchmitzV P, MandelbrotL, Kazatchkine M D, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol, 2000, 96(3): 403–409

[10] BekkersR L, MassugerL F, BultenJ, MelchersW J. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol, 2004, 14(2): 95–105

[11] StolerM H. Advances in cervical screening technology. Mod Pathol, 2000, 13(3): 275–284

[12] LiL K, DaiM, CliffordG M, YaoW Q, ArslanA, LiN, ShiJ F, SnijdersP J, MeijerC J, QiaoY L, FranceschiS. Human papillomavirus infection in Shenyang City, People’s Republic of China: A population-based study. Br J Cancer, 2006, 95(11): 1593–1597

[13] SellorsJ W, KarwalajtysT L, KaczorowskiJ A, MahonyJ B, LytwynA, ChongS, SparrowJ, LorinczA; Survey of HPV in Older Ontario Women (SHOOW) Group. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ, 2002, 167(8): 871–873

[14] FerreraA, VelemaJ P, FigueroaM, BulnesR, ToroL A, ClarosJ M, de BarahonaO, MelchersW J. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cancer in Honduras. Int J Epidemiol, 2000, 29(5): 817–825

[15] WalboomersJ M, JacobsM V, ManosM M, BoschF X, KummerJ A, ShahK V, SnijdersP J, PetoJ, MeijerC J, MuñozN. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12–19

[16] FranceschiS, HerreroR, La VecchiaC. Cervical cancer screening in Europe. What next? Eur J Cancer, 2000, 36(17): 2272–2275

[17] MuñozN, BoschF X, de SanjoséS, HerreroR, CastellsaguéX, ShahK V, SnijdersP J, MeijerC J; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 2003, 348(6): 518–527

[18] zur HausenH. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst, 2000, 92(9): 690–698

[19] KulasingamS L, HughesJ P, KiviatN B, MaoC, WeissN S, KuypersJ M, KoutskyL A. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA, 2002, 288(14): 1749–1757

[20] LiawK L, GlassA G, ManosM M, GreerC E, ScottD R, ShermanM, BurkR D, KurmanR J, WacholderS, RushB B, CadellD M, LawlerP, TaborD, SchiffmanM. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst, 1999, 91(11): 954–960

[21] ShermanM E, LorinczA T, ScottD R, WacholderS, CastleP E, GlassA G, Mielzynska-LohnasI, RushB B, SchiffmanM. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst, 2003, 95(1): 46–52

[22] KuhnL, DennyL, PollackA, LorinczA, RichartR M, WrightT C. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst, 2000, 92(10): 818–825

[23] PehW L, MiddletonK, ChristensenN, NichollsP, EgawaK, SotlarK, BrandsmaJ, PercivalA, LewisJ, LiuW J, DoorbarJ. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol, 2002, 76(20): 10401–10416

[24] WoodmanC B, CollinsS, WinterH, BaileyA, EllisJ, PriorP, YatesM, RollasonT P, YoungL S. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, 2001, 357(9271): 1831–1836

[25] YangY J, ZhaoJ, XueQ L. The associativity of the different subtypes of human papilloma virus infection and cervical lesions. Zhongguo Fu Chan Ke Li Chuang Za Zhi, 2006, 7(4): 253–256 (in Chinese)

[26] RuT H, WeiL H, WuR F, ZhouY Q. The subtype dominance of human papillomavirus infection in the different degrees of cervical lesions. Huazhong Keji Daxue Xebao (Yixueban), 2006, 35(6): 771–773 (in Chinese)

[27] TsaiH T, WuC H, LaiH L, LiR N, TungY C, ChuangH Y, WuT N, LinL J, HoC K, LiuH W, WuM T. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev, 2005, 14(11 Pt 1): 2544–2549

[28] SchellekensM C, DijkmanA, AzizM F, SiregarB, CornainS, Kolkman-UljeeS, PetersL A, FleurenG J. Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. Gynecol Oncol, 2004, 93(1): 49–53

[29] DelucaG D, LuceroR H, Martin de CivettaM T, VicenteL, de GorodnerO L, ScheloverE, AlonsoJ M. Human papillomavirus genotypes in women with cervical cytological abnormalities from an area with high incidence of cervical cancer. Rev Inst Med Trop Sao Paulo, 2004, 46(1): 9–12

[30] BulkS, BerkhofJ, BulkmansN W, ZielinskiG D, RozendaalL, van KemenadeF J, SnijdersP J, MeijerC J. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer, 2006, 94(1): 171–175

[31] AltekruseS F, LaceyJ V Jr, BrintonL A, GravittP E, SilverbergS G, BarnesW A Jr, GreenbergM D, HadjimichaelO C, McGowanL, MortelR, SchwartzP E, HildesheimA. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol, 2003, 188(3): 657–663

[32] LombardI, Vincent-SalomonA, ValidireP, ZafraniB, de la RochefordiéreA, CloughK, FavreM, PouillartP, Sastre-GarauX. Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol, 1998, 16(8): 2613–2619

[33] CliffordG M, SmithJ S, AguadoT, FranceschiS. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer, 2003, 89(1): 101–105

[34] WomackS D, ChirenjeZ M, GaffikinL, BlumenthalP D, McGrathJ A, ChipatoT, NgwalleS, MunjomaM, ShahK V. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer, 2000, 85(2): 206–210

[35] Damasus-AwataiG, Freeman-WangT. Human papilloma virus and cervical screening. Curr Opin Obstet Gynecol, 2003, 15(6): 473–477

[36] SchlechtN F, KulagaS, RobitailleJ, FerreiraS, SantosM, MiyamuraR A, Duarte-FrancoE, RohanT E, FerenczyA, VillaL L, FrancoE L. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA, 2001, 286(24): 3106–3114

[37] JosefssonA M, MagnussonP K, YlitaloN, SørensenP, Qwarforth-TubbinP, AndersenP K, MelbyeM, AdamiH O, GyllenstenU B. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet, 2000, 355(9222): 2189–2193

[38] HuangZ H, QianD Y, WangD, CenJ M, ShuY H. The related research about Human papilloma viral loading dose and cervical precancerosis lesions and cervical cancer. Zhongguo Fuyou Baojian, 2006, 21(11): 1557–1559 (in Chinese)

[39] SunC A, LiuJ F, WuD M, NiehS, YuC P, ChuT Y. Viral load of high-risk human papillomavirus in cervical squamous intraepithelial lesions. Int J Gyne Obstet, 2002, 76(1): 41–47

[40] SunC A, LaiH C, ChangC C, NeihS, YuC P, ChuT Y. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol, 2001, 83(1): 95–99

[41] SchlechtN F, TrevisanA, Duarte-FrancoE, RohanT E, FerenczyA, VillaL L, FrancoE L. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer, 2003, 103(4): 519–524

[42] DalsteinV, RiethmullerD, PrétetJ L, Le Bail CarvalK, SautièreJ L, CarbilletJ P, KantelipB, SchaalJ P, MouginC. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer, 2003, 106(3): 396–403

[43] JosefssonA M, MagnussonP K, YlitaloN, SørensenP, Qwarforth-TubbinP, AndersenP K, MelbyeM, AdamiH O, GyllenstenU B. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet, 2000, 355(9222): 2189–2193

[44] MobergM, GustavssonI, WilanderE, GyllenstenU. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer, 2005, 92(5): 891–894

[45] LorinczA T, CastleP E, ShermanM E, ScottD R, GlassA G, WacholderS, RushB B, GravittP E, SchusslerJ E, SchiffmanM. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet, 2002, 360(9328): 228–229

[46] HoG Y, BurkR D, KleinS, KadishA S, ChangC J, PalanP, BasuJ, TachezyR, LewisR, RomneyS. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst, 1995, 87(18): 1365–1371

[47] BurdE M. Human papillomavirus and cervical cancer. Clin Microbiol Rev, 2003, 16(1): 1–17

[48] LeeS A, KangD, SeoS S, JeongJ K, YooK Y, JeonY T, KimJ W, ParkN H, KangS B, LeeH P, SongY S. Multiple HPV infection in cervical cancer screened by HPVDNAChip. Cancer Lett, 2003, 198(2): 187–192

Acknowledgements

This work was supported by the Special Funds for State Key Development Program for Basic Research of China (973 Program) (No. 2009CB521800) and the National Natural Science Foundation of China (Grant Nos. 30672227, 30770913, 30628029, 30500596 and 30600667).

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg